New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2012
16:25 EDTOTT, AZN, WMT, ACHN, RDEA, TWC, BKS, KOn The Fly: Closing Wrap
Stocks on Wall Street were lower following a pair of political developments in Europe. France’s incumbent president, Nicolas Sarkozy, came in second in the first round of the nation's elections and the Dutch cabinet failed to gain approval for a budget which included austerity measures, leading to their resignations. The European news, along with some disappointing data there and from China, weighed on the futures, which in turn led to a sharply lower open for the broader market. The market continued to move lower in the first hour of trading but then found a level where it began to build. The averages moved in a generally upward trend for the remainder of the session, as investors waited for the next round of earnings reports and for news later this week from the FOMC... ECONOMIC EVENTS: Domestically, little economic data of note was reported. Internationally, Markit's European composite purchase managers' index fell to 47.4 points while a flash Chinese PMI reading rose to 49.1 in April, with both of those figures signaling contraction... COMPANY NEWS: The New York Times said Wal-Mart (WMT) attempted to cover up bribery that it discovered at Wal-Mart de Mexico (WMMVY) and the retailers' shares were the Dow's worst performer, falling $2.91, or 4.66%, to $59.54... Kellogg (K) cut its full-year guidance as it said Europe's challenges were "more significant" than it expected and it sees Q1 challenges in some categories in the U.S. Shares sank $3.29, or 6.09%, to $50.70... MAJOR MOVERS: Among the notable gainers were Ardea Biosciences (RDEA), up $10.78, or 51.73%, to $31.62, after AstraZeneca (AZN) agreed to acquire the company for $32 per share, and Barnes & Noble (BKS), up $2.07, or 18.25%, to $13.41, as CNBC reported that Jana Partners is increasing its stake in the company to about 12%. Noteworthy losers included Achillion (ACHN), down $1.53, or 18.54%, to $6.74, following the company's report of Phase II study data for its lead hepatitis C treatment, and Otelco (OTT), down $5.37, or 44.64%, to $6.66, after it said Time Warner Cable (TWC) will not renew its existing contract for wholesale network connections, which made up almost 12% of Otelco’s consolidated revenue last year... INDICES: The Dow fell 102.09, or 0.78%, to 12,927.17; the Nasdaq dropped 30.00, or 1.00%, to 2,970.45; and the S&P 500 shed 11.59, or 0.84%, to 1,366.94.
News For WMT;K;RDEA;AZN;BKS;ACHN;OTT;TWC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 25, 2015
10:26 EDTBKSBarnes & Noble sees FY16 retail comparable store sales 'approximately flat'
Subscribe for More Information
10:24 EDTBKSBarnes & Noble says separation proceeding 'at full pace'
Subscribe for More Information
08:33 EDTBKSBarnes & Noble sees separation complete by end of August
Subscribe for More Information
08:33 EDTBKSBarnes & Noble to name CEO Huseby as Execuve Chairman of B&N Education
Subscribe for More Information
08:32 EDTBKSBarnes & Noble sees FY16 retail core comparable bookstore sales up approx. 1%
For fiscal year 2016, the company expects Retail core comparable bookstore sales, which exclude sales of NOOK products, to increase approximately 1%, while College comparable store sales are also expected to increase approximately 1%. The company also expects full fiscal year EBITDA losses in the NOOK segment to decline versus the prior year.
08:31 EDTBKSBarnes & Noble reports Q4 EPS (37c), consensus (39c)
Subscribe for More Information
June 24, 2015
15:27 EDTBKSBarnes & Noble July 26 straddle priced for 7.8% movement into Q4
Subscribe for More Information
14:03 EDTBKSBarnes & Noble July volatility elevated into Q4 and outlook
Barnes & Noble July call option implied volatility is at 40, August is at 35, October is at 36; compared to its 52-range-week of 29 to 54, suggesting non-directional price movement into the expected release of Q4 results on June 25.
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
06:22 EDTWMTWal-Mart to charge fees to ‘almost all’ vendors, Reuters reports
Subscribe for More Information
June 23, 2015
18:04 EDTWMTWal-Mart poaches technology talent from eBay, WSJ says
Subscribe for More Information
16:29 EDTWMTOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
13:37 EDTWMTOn The Fly: Top stock stories at midday
Subscribe for More Information
10:00 EDTTWCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:39 EDTTWCTime Warner Cable downgraded to Sector Perform from Outperform at Scotiabank
07:36 EDTACHNJMP Securities to hold a conference
Subscribe for More Information
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:05 EDTWMTGreen Dot price target raised to $24 from $22 at Piper Jaffray
Subscribe for More Information
06:31 EDTWMTGreen Dot contract terms better than feared, says JPMorgan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use